Acute Respiratory Distress Syndrome, Circulatory Failure, Respiratory Failure, Respiratory Insufficiency
Conditions
Brief summary
Incidence of thromboembolic events during ECMO therapy i.e.: • Clinically relevant thromboembolic events (Clinical suspicion; confirmation via imaging) • Pulmonary embolism, deep vein thrombosis • Intracardiac thrombosis • Arterial thromboembolism including myocardial and cerebral infarction • Deep vein thrombosis (detected during daily routine sonography) • Need to exchange ECMO circuit due to acute or incipient clotting
Detailed description
Incidence of bleeding events classified according to BARC Criteria
Interventions
DRUGHeparin Gilvasan 1000 IE/ml – Injektions-/Infusionslösung
DRUGInhixa 100
DRUG000 IU (1000 mg)/10 mL solution for injection in multidose container
DRUGArgatra Multidose 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung.
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of thromboembolic events during ECMO therapy i.e.: • Clinically relevant thromboembolic events (Clinical suspicion; confirmation via imaging) • Pulmonary embolism, deep vein thrombosis • Intracardiac thrombosis • Arterial thromboembolism including myocardial and cerebral infarction • Deep vein thrombosis (detected during daily routine sonography) • Need to exchange ECMO circuit due to acute or incipient clotting | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of bleeding events classified according to BARC Criteria | — |
Countries
Austria
Outcome results
None listed